Elucidation of the Pattern of the Onset of Male Lower Urinary Tract Symptoms Using Cluster Analysis: Efficacy of Tamsulosin in Each Symptom Group - 21/08/15
, Masao Kataoka a, Soichiro Ogawa a, Hidenori Akaihata a, Yuichi Sato a, Michihiro Yabe a, Junya Hata a, Tomoyuki Koguchi a, Yoshiyuki Kojima a, Chihaya Shiragasawa b, Toshimitsu Kobayashi b, Osamu Yamaguchi cAbstract |
Objective |
To present a new grouping of male patients with lower urinary tract symptoms (LUTS) based on symptom patterns and clarify whether the therapeutic effect of α1-blocker differs among the groups.
Methods |
We performed secondary analysis of anonymous data from 4815 patients enrolled in a postmarketing surveillance study of tamsulosin in Japan. Data on 7 International Prostate Symptom Score (IPSS) items at the initial visit were used in the cluster analysis. IPSS and quality of life (QOL) scores before and after tamsulosin treatment for 12 weeks were assessed in each cluster. Partial correlation coefficients were also obtained for IPSS and QOL scores based on changes before and after treatment.
Results |
Five symptom groups were identified by cluster analysis of IPSS. On their symptom profile, each cluster was labeled as minimal type (cluster 1), multiple severe type (cluster 2), weak stream type (cluster 3), storage type (cluster 4), and voiding type (cluster 5). Prevalence and the mean symptom score were significantly improved in almost all symptoms in all clusters by tamsulosin treatment. Nocturia and weak stream had the strongest effect on QOL in clusters 1, 2, and 4 and clusters 3 and 5, respectively.
Conclusion |
The study clarified that 5 characteristic symptom patterns exist by cluster analysis of IPSS in male patients with LUTS. Tamsulosin improved various symptoms and QOL in each symptom group. The study reports many male patients with LUTS being satisfied with monotherapy using tamsulosin and suggests the usefulness of α1-blockers as a drug of first choice.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: Ken Aikawa has received speaker's honoraria from Astellas, Pfizer, Asahi Kasei, and Takeda. Yoshiyuki Kojima has received grants from Astellas, Takeda, Asahi Kasei, and Kissei and speaker's honoraria from Astellas, Pfizer, Takeda, Kissei, Asahi Kasei, Johnson & Johnson, and Sanofi. Chihaya Shiragasawa and Tomoyuki Koguchi are employees of Astellas. Osamu Yamaguchi is a consultant for Astellas, Pfizer, Ferring, and Hisamitsu, is a member of the advisory boards of Astellas, and has received grants from Astellas, Kissei, Kyorin, and has received payments for lectures from Astellas, Kyorin, and Kissei. The remaining authors declare that they have no relevant financial interests. |
|
| Funding Support: This study was funded and conducted by Astellas Pharma Inc. The study data were analyzed by Astellas Pharma Inc. |
Vol 86 - N° 2
P. 349-353 - août 2015 Retour au numéro
Article précédent
- Prostatic Arterial Embolization vs Open Prostatectomy: A 1-Year Matched-pair Analysis of Functional Outcomes and Morbidities
- Giorgio Ivan Russo, Dmitry Kurbatov, Salvatore Sansalone, Alexander Lepetukhin, Sergey Dubsky, Ivan Sitkin, Costanza Salamone, Livio Fiorino, Roman Rozhivanov, Sebastiano Cimino, Giuseppe Morgia
- Validation of a Visual Prostate Symptom Score in Men With Lower Urinary Tract Symptoms in a Health Safety Net Hospital
- Rachel E. Selekman, Catherine R. Harris, Pauline Filippou, Thomas Chi, Amjad Alwaal, Sarah D. Blaschko, Benjamin N. Breyer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?